Komal L. Jhaveri
AuthID: R-00K-EG7
1
TITLE: Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2-advanced breast cancer: a matching-adjusted indirect comparison
AUTHORS: Rugo, Hope S. S.; Harmer, Victoria; O'Shaughnessy, Joyce; Jhaveri, Komal; Tolaney, Sara M. M.; Cardoso, Fatima; Bardia, Aditya; Maheshwari, Vikalp Kumar; Tripathi, Sandeep; Haftchenary, Sina; Pathak, Purnima; Fasching, Peter A. A.;
PUBLISHED: 2023, SOURCE: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, VOLUME: 15
AUTHORS: Rugo, Hope S. S.; Harmer, Victoria; O'Shaughnessy, Joyce; Jhaveri, Komal; Tolaney, Sara M. M.; Cardoso, Fatima; Bardia, Aditya; Maheshwari, Vikalp Kumar; Tripathi, Sandeep; Haftchenary, Sina; Pathak, Purnima; Fasching, Peter A. A.;
PUBLISHED: 2023, SOURCE: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, VOLUME: 15
INDEXED IN: 
Scopus 
WOS
Scopus WOS2
TITLE: Poster Discussion Session Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/ human epidermal growth factor receptor-negative (HR+/HER2-) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC).
AUTHORS: Rugo, Hope S.; O'Shaughnessy, Joyce; Jhaveri, Komal L.; Tolaney, Sara M.; Cardoso, Fatima; Bardia, Aditya; Maheshwari, Vikalp Kumar; Tripathi, Sandeep; Pathak, Purnima; Haftchenary, Sina; Fasching, Peter A.;
PUBLISHED: 2022, SOURCE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 40, ISSUE: 16
AUTHORS: Rugo, Hope S.; O'Shaughnessy, Joyce; Jhaveri, Komal L.; Tolaney, Sara M.; Cardoso, Fatima; Bardia, Aditya; Maheshwari, Vikalp Kumar; Tripathi, Sandeep; Pathak, Purnima; Haftchenary, Sina; Fasching, Peter A.;
PUBLISHED: 2022, SOURCE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 40, ISSUE: 16
INDEXED IN: WOS
WOS